GLSI
Greenwich LifeSciences, Inc.
Key Financials
Operating Income
$-19447918
↓ 21.5%
Shareholders' Equity
$353217.00
↓ 86.1%
Total Liabilities
$5.8M
↑ 188.8%
Total Assets
$6.2M
↑ 50.9%
EPS (Diluted)
$-1.43
↓ 88.2%
Net Income
$-19358218
↓ 89.7%
Cash & Equivalents
$6.2M
↑ 51.0%
Operating Cash Flow
$-9913453.00
↓ 47.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 6/4/2026 | View on SEC |
| 10-K | 6/1/2026 | View on SEC |
| NT 10-K | 3/31/2026 | View on SEC |
| 4 | 1/15/2026 | View on SEC |
| 4 | 1/14/2026 | View on SEC |
| 4 | 1/5/2026 | View on SEC |
| 4 | 1/2/2026 | View on SEC |
| 4 | 12/19/2025 | View on SEC |
| 8-K | 12/18/2025 | View on SEC |
| 4 | 11/28/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | GLSI |
| Company Name | Greenwich LifeSciences, Inc. |
| CIK | 1799788 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 203-434-3290 |